A phase II trial of the rapamycin analog CCI-779 in previously treated mantle cell non-Hodgkin's lymphoma: Interim analysis of 18 patients.

被引：0
|
作者：
Witzig, TE
Geyer, SM
Salim, M
Inwards, DJ
Fonseca, R
Kauffnan, SH
Kurtin, P
Colgan, JP
Call, TG
Moore, D
White, WL
机构：
[1] Mayo Clin & Mayo Fdn, Rochester, MN 55905 USA
[2] Allan Blair Canc Ctr, Regina, SK, Canada
[3] Canc Ctr Kansas, Wichita, KS USA
来源：
BLOOD | 2003年 / 102卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
2374
引用
收藏
页码：643A / 643A
页数：1
相关论文
共 50 条
  • [21] Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma
    O'Connor, OA
    Wright, J
    Moskowitz, C
    Muzzy, J
    MacGregor-Cortelli, B
    Stubblefield, M
    Straus, D
    Portlock, C
    Hamlin, P
    Choi, E
    Dumetrescu, O
    Esseltine, D
    Trehu, E
    Adams, J
    Schenkein, D
    Zelenetz, AD
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (04) : 676 - 684
  • [22] Late phase II study of amrubicin in previously untreated patients with non-Hodgkin's lymphoma (NHL).
    Suzumiya, J.
    Suzuki, K.
    Uike, N.
    Kawano, F.
    Takeo, T.
    Okamura, S.
    Sakai, C.
    Mori, M.
    Tamura, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (15)
  • [23] Phase II Study of Vorinostat for Treatment of Relapsed or Refractory Indolent Non-Hodgkin's Lymphoma and Mantle Cell Lymphoma
    Kirschbaum, Mark
    Frankel, Paul
    Popplewell, Leslie
    Zain, Jasmine
    Delioukina, Maria
    Pullarkat, Vinod
    Matsuoka, Deron
    Pulone, Bernadette
    Rotter, Arnold J.
    Espinoza-Delgado, Igor
    Nademanee, Auayporn
    Forman, Stephen J.
    Gandara, David
    Newman, Edward
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (09) : 1198 - 1203
  • [24] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
    Kimihiro Matsumoto
    Nobuyuki Takayama
    Yoshinobu Aisa
    Hironori Ueno
    Masao Hagihara
    Kentaro Watanabe
    Aya Nakaya
    Kenko Chen
    Takayuki Shimizu
    Yuiko Tsukada
    Yuji Yamada
    Tomonori Nakazato
    Akaru Ishida
    Yoshitaka Miyakawa
    Kenji Yokoyama
    Hideaki Nakajima
    Yoshihiro Masuda
    Takahiro Yano
    Shinichiro Okamoto
    International Journal of Hematology, 2015, 101 : 554 - 562
  • [25] A phase II study of bendamustine plus rituximab in Japanese patients with relapsed or refractory indolent B-cell non-Hodgkin lymphoma and mantle cell lymphoma previously treated with rituximab: BRB study
    Matsumoto, Kimihiro
    Takayama, Nobuyuki
    Aisa, Yoshinobu
    Ueno, Hironori
    Hagihara, Masao
    Watanabe, Kentaro
    Nakaya, Aya
    Chen, Kenko
    Shimizu, Takayuki
    Tsukada, Yuiko
    Yamada, Yuji
    Nakazato, Tomonori
    Ishida, Akaru
    Miyakawa, Yoshitaka
    Yokoyama, Kenji
    Nakajima, Hideaki
    Masuda, Yoshihiro
    Yano, Takahiro
    Okamoto, Shinichiro
    INTERNATIONAL JOURNAL OF HEMATOLOGY, 2015, 101 (06) : 554 - 562
  • [26] A phase II multicenter study of CAMPATH-1H antibody in previously treated patients with nonbulky non-Hodgkin's lymphoma
    Khorana, A
    Bunn, P
    McLaughlin, P
    Vose, J
    Stewart, C
    Czuczman, MS
    LEUKEMIA & LYMPHOMA, 2001, 41 (1-2) : 77 - 87
  • [27] 2-Chlorodeoxyadenosine in refractory non-Hodgkin's lymphoma: A phase II study on 50 patients.
    Bosly, A
    Sonet, A
    Ferrant, A
    Delannoy, A
    Cornu, G
    Canon, JL
    Martiat, P
    Straetmans, N
    Ravoet, C
    Mineur, P
    Laszlo, C
    Jamart, J
    Doyen, C
    Michaux, JL
    BLOOD, 1995, 86 (10) : 212 - 212
  • [28] Anti-tumor activity of low-dose single agent CCI-779 for relapsed mantle cell/Lymphoma: A phase II trial in the North Central Cancer Treatment Group.
    Witzig, TE
    Ansell, SM
    Geyer, SM
    Kurtin, PJ
    Rowland, KM
    Flynn, PJ
    Morton, RF
    Dakhil, SR
    Gross, HM
    Maurer, MJ
    Kaufmann, SH
    JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (16) : 561S - 561S
  • [29] An open-label phase 2 trial of entospletinib in indolent non-Hodgkin lymphoma and mantle cell lymphoma
    Andorsky, David J.
    Kolibaba, Kathryn S.
    Assouline, Sarit
    Forero-Torres, Andres
    Jones, Vicky
    Klein, Leonard M.
    Patel-Donnelly, Dipti
    Smith, Mitchell
    Ye, Wei
    Shi, Wen
    Yasenchak, Christopher A.
    Sharman, Jeff P.
    BRITISH JOURNAL OF HAEMATOLOGY, 2019, 184 (02) : 215 - 222
  • [30] A Phase II Trial of Induction Plus Maintenance Rituximab and Bortezomib in Patients with Relapsed/Refractory Mantle Cell (MCL) and Follicular (FL) Non-Hodgkin's Lymphoma
    Blum, Kristie A.
    Baiocchi, Robert A.
    Alinari, Lapo
    Lin, Thomas S.
    Porcu, Pierluigi
    Jones, Jeffrey
    Flynn, Joseph
    Hicks, William
    Lucas, Margaret S.
    Wei, Lai
    Johnston, Jeffrey S.
    Byrd, John C.
    BLOOD, 2008, 112 (11) : 1049 - 1050
12345